A father’s prostate cancer diagnosis does modestly raise your statistical risk of breast cancer, though the increase is far smaller than most people assume. A large analysis of participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial found that having a first-degree relative with prostate cancer was associated with about a 13 percent higher probability of being diagnosed with breast cancer. That link exists mainly because a handful of inherited gene mutations can drive both cancers, and those mutations pass equally from fathers and mothers. The story behind that connection, and what you should actually do about it, is more nuanced than a single number can capture.
Why Prostate Cancer and Breast Cancer Show Up in the Same Families
Prostate tissue and breast tissue are both hormone-sensitive organs, and the genes responsible for repairing damaged DNA in those tissues overlap substantially. When one of those repair genes carries a harmful inherited mutation, the resulting cancer risk does not respect the boundary between “male” and “female” cancers. The best-known examples are BRCA1 and BRCA2. Most people associate those names with breast and ovarian cancer in women, but BRCA2 mutations in particular have been linked to a higher risk of prostate cancer, especially prostate cancer diagnosed at a younger age.1PubMed Central. BRCA2 mutations in familial breast cancer with prostate cancer: a case report and literature review A father who develops prostate cancer because of a BRCA2 mutation has a 50 percent chance of passing that same mutation to each of his children. A daughter who inherits it then faces a significantly elevated lifetime risk of breast and ovarian cancer.
BRCA1 works the same way, though it is more commonly associated with breast and ovarian cancer than with prostate cancer. Case reports have documented fathers carrying BRCA1 mutations who remained cancer-free themselves while their daughters developed aggressive, early-onset breast cancer after inheriting the mutation.2PubMed Central. A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype In other words, the father can be a silent carrier of a gene mutation that does not harm him but creates serious risk for his daughters. When a father does develop prostate cancer and also carries one of these mutations, both things can trace back to the same inherited variant.
Beyond BRCA: Other Shared Gene Mutations
BRCA1 and BRCA2 get the headlines, but several other genes raise risk for both breast and prostate cancer. A large study involving tens of thousands of breast and prostate cancer cases found that specific variants in three genes, PALB2, CHEK2, and ATM, were associated with increased breast cancer risk. Some of the same gene family also showed up in prostate cancer: CHEK2 variants were associated with roughly two to three times the risk of prostate cancer in men of both European and African ancestry.3PubMed Central. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS For context, one ATM variant carried a breast cancer risk increase of roughly elevenfold in European women, while certain PALB2 variants raised breast cancer risk by three- to fourfold in the same population.
These genes all participate in the same fundamental biological task: fixing broken DNA strands. When the repair machinery is faulty, errors accumulate faster in rapidly dividing cells, and both breast and prostate tissue are places where cells divide frequently under hormonal stimulation. A family that carries one of these mutations may see breast cancer in women and prostate cancer in men across generations, even though the two diseases look clinically very different. The shared genetic root is what matters.
How Much Does a Father’s Prostate Cancer Actually Raise Your Risk?
Population-level data from the PLCO trial, which followed more than 150,000 participants, put some numbers on the cross-cancer family history effect. Women who reported a first-degree relative with prostate cancer had a hazard ratio of about 1.13 for being diagnosed with breast cancer, meaning roughly a 13 percent relative increase in diagnosis probability compared with women who had no such family history. The study also found a reciprocal relationship: men who reported a first-degree relative with breast cancer had a roughly 9 percent higher probability of being diagnosed with prostate cancer.4PubMed. Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants
A 13 percent relative increase sounds concerning, but it is important to understand what that means in practice. If a woman’s baseline lifetime risk of breast cancer is around 12 to 13 percent (the commonly cited average for American women), a 13 percent relative increase brings that to roughly 14 percent. That is not nothing, but it is a very different picture from, say, carrying a BRCA2 mutation, which can push lifetime breast cancer risk above 60 or 70 percent. The PLCO study also found that having a relative with prostate cancer was not associated with a higher risk of dying from breast cancer, only with being diagnosed.4PubMed. Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants The cancers that get detected may tend to be less aggressive on average, or the association may partly reflect heightened screening in families aware of their cancer history.
The takeaway is that a father’s prostate cancer is a signal, not a sentence. It is one data point that your doctor should know about, not a reason to panic.
The Paternal Side Is Routinely Underestimated
One of the most practically important findings in this area is that people consistently underreport their father’s side of the family when asked about cancer history. Research from the Family Healthware Impact Trial found that women reported “don’t know” about cancer history for paternal relatives almost three times as often as for maternal relatives. Women averaged about one “don’t know” response per paternal relative compared with less than half of one per maternal relative.5Genetics in Medicine. Components of family history associated with women’s disease perceptions for cancer: A report from the Family Healthware™ Impact Trial The same study found that men themselves tended to answer “don’t know” about family history more often than women did, suggesting fathers may be a less reliable source of family health information to begin with.
This knowledge gap has real consequences. If your father had prostate cancer and you never mention it to your doctor because it seems unrelated to your own health, or because you simply do not know much about your father’s medical history, you may miss an opportunity for earlier screening or genetic counseling. The study’s authors noted that women also perceived lower cancer risk when the family history came from the paternal side than when the same history came from the maternal side, even though genetically the risk transmission is identical.5Genetics in Medicine. Components of family history associated with women’s disease perceptions for cancer: A report from the Family Healthware™ Impact Trial That perception gap is a blind spot worth correcting.
When Genetic Testing Makes Sense
Not everyone with a father who had prostate cancer needs genetic testing. Current guidelines focus testing on situations where there is a reasonable probability of finding something actionable. A scoping review of genetic testing guidelines for prostate cancer found that germline testing is recommended for men with high-risk or metastatic prostate cancer regardless of family history. Testing is also recommended when there is a family history of early-onset breast cancer (diagnosed at age 50 or younger), ovarian cancer at any age, pancreatic cancer, or prostate cancer diagnosed before age 60 or that caused death.6Nature. Guidelines for genetic testing in prostate cancer: a scoping review Ashkenazi Jewish ancestry is another trigger, because three specific BRCA founder mutations are far more common in that population.
For women wondering about their own risk, the relevant question is whether your father’s prostate cancer was the kind that suggests a hereditary mutation. Red flags include prostate cancer diagnosed before age 60, aggressive or metastatic disease, and other cancers clustering in the family, particularly breast, ovarian, or pancreatic cancer on either side. If your father was diagnosed in his mid-seventies with slow-growing prostate cancer and there is no other cancer in the family, the probability of a shared hereditary mutation is much lower. A genetic counselor can look at the full family picture and help decide whether formal testing is warranted.
The National Comprehensive Cancer Network also recommends genetic counseling and testing for people whose relatives had metastatic, regional, very-high-risk, or high-risk prostate cancer at any age, broadening the net beyond just the patient himself to family members who want to understand their own risk.
Why Direct-to-Consumer DNA Tests Are Not Enough
If you have looked into genetic testing on your own, you may have considered a consumer DNA kit. These tests typically screen for only three specific BRCA mutations, all of which are founder mutations common in people of Ashkenazi Jewish descent. For everyone else, the coverage is alarmingly incomplete. A retrospective study found that direct-to-consumer genetic testing missed more than 90 percent of harmful BRCA1 and BRCA2 variants in individuals who were not of Ashkenazi Jewish ancestry.7PubMed Central. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer Even among Ashkenazi Jewish individuals, about 10 percent of BRCA mutations were still missed.8Journal of Clinical Oncology. Limitations of direct-to-consumer (DTC) genetic testing for hereditary breast and ovarian cancer
A separate analysis of both indication-based and screening cohorts confirmed these numbers, finding a clinical false-negative rate of about 88 percent for any BRCA1/2 mutation when only the three Ashkenazi founder variants were tested. Among non-Ashkenazi individuals, the false-negative rate reached 94 percent.9Cancer Research. Limitations of direct-to-consumer genetic screening for HBOC: False negatives, false positives and everything in between The practical danger is false reassurance. A negative result from a consumer test can make you feel safe when you actually carry a harmful variant the test was never designed to find. Clinical genetic testing ordered through a healthcare provider sequences the entire BRCA1 and BRCA2 genes and often includes a panel of other cancer-risk genes like PALB2, CHEK2, and ATM. If your family history raises red flags, a consumer kit is not a substitute for clinical testing.
What a Positive Result Would Mean in Practice
If genetic testing does reveal that you carry a BRCA1, BRCA2, or other high-risk mutation inherited from your father, the clinical path forward is well-defined. For BRCA2 carriers, lifetime breast cancer risk is substantially elevated, and enhanced screening typically begins at a younger age than it does for average-risk women. That usually means annual breast MRI starting in your twenties or thirties, alongside mammography. Some women choose risk-reducing surgery. The specifics depend on which gene is involved, what variant is present, and your individual preferences.
For moderate-penetrance genes like CHEK2 or ATM, the management is different. The risk increase is real but more modest than with BRCA mutations, so the clinical recommendations tend to focus on enhanced screening rather than surgery. Polygenic risk assessment, which combines the effects of many common genetic variants, has also been studied as a way to refine predictions, but research has found that these scores add only limited predictive power for breast and prostate cancer beyond what replicated individual gene variants already provide.10PubMed Central. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk In practice, that means single-gene testing for known high- and moderate-risk variants still forms the backbone of clinical genetic assessment for hereditary cancer risk.
Gathering Your Father’s Medical History
Because paternal family history is so often incomplete, taking some active steps to fill in the gaps is worth the effort. If your father is alive, ask him directly about his prostate cancer diagnosis: his age at diagnosis, whether the cancer was described as aggressive or slow-growing, and whether he has ever had genetic testing. Ask about his siblings and his parents. Did any of his relatives have breast, ovarian, pancreatic, or colorectal cancer? These details matter to a genetic counselor far more than a vague “my dad had cancer.”
If your father is not available to ask, other relatives on his side may know. Aunts, uncles, and older cousins sometimes have family health information that never got passed along. Medical records from your father’s oncologist can also be requested, particularly if he was treated at a cancer center that already performed tumor genomics or germline testing. Some families discover after a father’s death that testing was done but the results were never shared with other family members. If a harmful variant was found in your father, knowing the exact mutation allows a much simpler and cheaper targeted test for you, rather than sequencing entire genes from scratch.
Other Cancers That Cluster with Prostate and Breast Cancer
The same inherited mutations that connect prostate cancer and breast cancer also raise risk for several other cancers. BRCA2 mutations increase the risk of pancreatic cancer and melanoma. BRCA1 mutations raise ovarian cancer risk substantially. Lynch syndrome, caused by mutations in DNA mismatch repair genes, increases risk for colorectal, endometrial, ovarian, and stomach cancers, and recent evidence suggests a connection to prostate cancer as well. The genetic testing guidelines referenced earlier reflect this overlap: a family history of pancreatic cancer at any age, or Lynch syndrome-related cancers before age 50, are both flagged as reasons to consider testing.6Nature. Guidelines for genetic testing in prostate cancer: a scoping review
If your father had prostate cancer and there are also cases of pancreatic, ovarian, or early-onset colorectal cancer in his family, the probability of a shared hereditary mutation goes up considerably. That pattern should prompt a conversation with a genetic counselor even if you feel healthy and have no personal history of cancer. The whole point of identifying these mutations early is to catch cancers at their most treatable stage or, in some cases, to prevent them entirely with prophylactic measures.
When Your Father’s Prostate Cancer Is Probably Not Relevant to Your Breast Cancer Risk
Most prostate cancer is not hereditary. Prostate cancer is extremely common in older men, with the majority of cases diagnosed after age 65 and driven largely by aging, hormonal factors, and environmental influences rather than a single inherited mutation. If your father was diagnosed in his seventies with a low-grade, slow-growing tumor and there is no notable cancer history on either side of the family, the chances that his cancer reflects a mutation you should worry about are low.
The features that distinguish a likely hereditary case from a likely sporadic one include young age at diagnosis (generally under 60), aggressive disease at presentation, and multiple cancers in the same family line. A father who had garden-variety prostate cancer in his late sixties and no other family cancer history is in a very different category from a father who was diagnosed at 52 with high-grade disease and had a sister who died of ovarian cancer. Both are “my dad had prostate cancer,” but they carry vastly different implications for your own risk. Bringing the details rather than just the diagnosis to your doctor makes the difference between a meaningful risk assessment and a conversation that goes nowhere.